Form D · Pharmaceuticals
Telsar Pharma, Inc.
Bridgewater, NJ · CIK 0001549817
Offering snapshot reported May 18, 2012 · SEC filing
- Reported sold
- $14M Offering amount: $14M
- Investors reported
- 26 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 24, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 18, 2012 | Initial | $14,002,500 | No comparison | 26 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-178492
Source: Form D, filed May 18, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey Bird | Director |
| Christopher Del Mastro | Executive |
| Robert Desjardins | Director, Executive, Promoter |
| Arnold Oronsky | Director |
| Donna L. Tempel | Director, Executive, Promoter |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
520 Us Highway 22 Suite 201
Bridgewater, NJ, 08807
Bridgewater, NJ, 08807